Beyond Mutations: Additional Mechanisms and Implications of SWI/SNF Complex Inactivation

Area of Science:

• Molecular Biology
• Cancer Biology
• Epigenetics

Background:

• The SWI/SNF complex is a key regulator of gene expression, influencing DNA accessibility for transcription factors.
• It plays a critical role in diverse cellular processes, including DNA repair, differentiation, and growth control, making it vital in cancer prevention.
• Alterations in SWI/SNF subunits are implicated in cancer development, highlighting the complex's significance in oncogenesis.

Purpose of the Study:

• To review the mechanisms of SWI/SNF subunit inactivation in cancer, focusing on mutations versus non-mutational silencing.
• To explore the role of epigenetic modifications in SWI/SNF subunit loss.
• To discuss the therapeutic potential of targeting SWI/SNF, including synthetic lethality and the clinical utility of BRM polymorphisms.

Main Methods:

• Literature review of Next-Generation sequencing studies.
• Analysis of mutation frequencies versus subunit loss in various tumor types.
• Exploration of epigenetic regulatory mechanisms affecting SWI/SNF subunits.
• Review of synthetic lethality approaches and biomarker development.

Main Results:

• Mutations in SWI/SNF subunits are common across many cancer types.
• Subunit loss often exceeds mutation frequency, suggesting significant roles for non-mutational inactivation mechanisms.
• Epigenetic silencing is a likely contributor to SWI/SNF subunit loss, particularly for BRM.
• BRM polymorphisms are emerging as potential clinical biomarkers for cancer risk.

Conclusions:

• Non-mutational mechanisms, likely epigenetic, are critical for SWI/SNF subunit inactivation in cancer.
• The reversibility of epigenetic silencing presents a promising avenue for targeted cancer therapies.
• Understanding these inactivation pathways is essential for developing novel therapeutic strategies against SWI/SNF-associated cancers.